Media Advisory: DoseMe Bioinformatician and Chief Science and Strategy Officer Co-Author Poster to Be Presented at the 25th ESCMID Annual Meeting

Poster walkthrough session: Lessons from a large multi-national database of children: standard paediatric dosing for vancomycin results in unacceptable exposure variability led by Dr. Marc Scheetz, Professor and Director of Pharmacometrics Center of Excellence, Midwestern University

Downers Grove, IL,  Jupiter, FL and Brisbane, Australia – April 3, 2025

DoseMe, a leading provider of model-informed precision dosing (MIPD), today announced Dr. Marc Scheetz, will present, Lessons from a large multi-national database of children: standard paediatric dosing for vancomycin results in unacceptable exposure variability, at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) on April 13.

ECCMID is the annual meeting of ESCMID, the European Society of Clinical Microbiology and Infectious Diseases, a registered non-profit organization in Basel, Switzerland.  Leading experts will come together in Vienna at Messe Wien Exhibition & Congress Center from 11–15 April 2025.

Session Details:
Session Title: Paediatric ID
Date and Time: Sunday, 13 April, 13:30–14:30
Poster title: P2449 Lessons from a large multi-national database of children: standard paediatric dosing for vancomycin results in unacceptable exposure variability
 
Who: Dr. Marc Scheetz, Professor and Director of Pharmacometrics Center of Excellence, Midwestern University. Abstract co-authored Dr. Justin Shiau, post-doctoral fellow, Dr. Sharmeen Roy, PharmD,BCPS, Chief Strategy and Science Officer and Paul Sabourenkov, Lead Bioinformatician at DoseMe.

Where: The session will be promoted during the poster session in Hall D. During this 1-hour session the chair will guide the group through 10 selected posters, where authors will present their findings and facilitate discussions.

When: April 13 at 8:30 AM

“Data from a large multinational pediatric cohort reveal that standard vancomycin dosing leads to unacceptable variability in drug exposure, highlighting the urgent need for precision dosing strategies to optimize efficacy and minimize toxicity,” states Scheetz.  “It’s time to implement model-informed precision dosing.”


Additional Resources
Connect with DoseMe on LinkedIn
Follow DoseMe on Twitter
Bookmark the DoseMe Blog
Visit the DoseMe Newsroom
Contact DoseMe

About DoseMe

DoseMe combines smart technology with science, leveraging clinically-validated PK/PD models, patient characteristics, drug concentrations, and genotype to accurately individualize a dose in seconds. The platform is HIPAA, ISO & FDA compliant and the only Bayesian dosing platform to be HITRUST CSF certified. For more information on successful applications of its products, DoseMeRx and DoseMe Analytics, visit https://doseme-rx.com/success-stories